Byk Gulden Lomberg Chemische Fabrik Gmbh

Byk Gulden Lomberg Chemische Fabrik Gesellschaft MIT Beschrankter Haftung

Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Astrazeneca Ab

Altana Pharma Ag

Nycomed Gmbh

Takeda Gmbh

Klaus Eistetter

Rango Dietrich

Beate Schmidt

Erich Rapp

Hartmut Ney

Hans-Peter Kley

Hartmann Schaefer

Horst Wolf

Gerhard Pohlmann

Wolfgang Koch

Horst Windt

Ernst Sturm

Wilhelm Wurst

Oliver Nolte

Heinz Gunter Menge

Dietrich H&auml;fner

Heinz-Gunter Menge

Stefan Kaupp

Ruediger Nave

The invention relates to a devicefor dosing and dry nebulization of nebulizable materialchosen from the group comprising anti-infective agents and immunomodulators, comprising a nebulization channel, which has a first attachment piece and a second attachment piece, and a source of compressed carrier gas connected to the first attachment piece via a valvefor the purpose of sending a carrier gas pressure pulse into the nebulization channel. The device is characterized in that between the first attachment piece and second attachment piece, and above the nebulization channel, a reservoiropen only towards the nebulization channel, which contains the nebulizable material, is connected to the nebulization channel such that it is gas-tight with respect to the environment, and that, when the valve is closed, a pressure compensation takes place in the nebulization channel and in the reservoir. The invention also relates to a method for dosing and dry nebulization of such a nebulizable material by means of such a device.

Device for dosing and dry nebulization

Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.

Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient

Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient

Novel compositions for the treatment of IRDS and ARDS are indicated which contain N-(3,5-dichloro-pyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide and/or its pharmacologically tolerable salts and lung surfactant.

Compositions

Compositions for treating IRDS and ARDS contain N-(3,5-dichloropyrid-4-yl)3-cyclopropylmethoxy-4-difluoromethoxybenzamide and/or a pharmacologically tolerable salt thereof and lung surfactant.

Compositions for the treatment of ARDS or IRDS containing 3-(cycloproplymethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamide and lung surfactant

A powdered pulmonary surfactant preparation containing a hydrophobic protein serving as a pulmonary surfactant is obtained by spray drying an organic solution or suspension containing a hydrophobic protein serving as a pulmonary surfactant and possibly other components. Obtained power preparations exhibit very good stability under storage, are easy to reconstitute and are also suitable for administration by inhalation.

Process for the production of powdered pulmonary surfactant preparations

Use of oxirancarboxylic acids for the treatment of hyperlipemia

Substituted oxiranecarboxylic acids, their preparation and their use as

Quinolinone-alkanecarboxylic acids of the formula I ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are identical or different and denote hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group with 1 to 4 carbon atoms, an amino group, a dialkylamino group, the alkyl radicals having 1 to 4 carbon atoms, or a nitro group,

Substituted quinolinone-alkanecarboxylic acids and medicaments

Phenalkoxyalky- and phenoxyalkyl-substituted oxiranecarboxylic acids of the formula ##STR1## wherein R.sup.1 denotes a hydrogen atom (--H), a halogen atom, a lower alkyl group, a lower alkoxy group, a nitro group or a trifluoromethyl group,

Phenalkoxyalkyl- and phenoxyalkyl-substituted oxiranecarboxylic acids,

4-Phenoxypiperidines of the general formula I ##STR1## wherein R.sup.1 denotes a hydrogen atom, an alkyl group with 1 to 5 carbon atoms, an alkenyl group with 3 to 5 carbon atoms, a cycloalkylmethyl group with 3 to 7 carbon atoms in the cycloalkyl part or a phenylalkyl group with 1 to 3 carbon atoms in the alkyl part,

Anti-depressant and analgesic 4-phenoxypiperidines

Substituted oxiranecarboxylic acids of the formula ##STR1## wherein R.sup.1 denotes a hydrogen atom (--H), a halogen atom, a hydroxyl roup, a lower alkyl group, a lower alkoxy group or a trifluoromethyl group,

Substituted oxiranecarboxylic acids, their use and medicaments

2-Benzylpyrrolidines bearing from 1 to 4 nuclear substituents on the benzyl ring are pharmacologically active, particularly on the CNS, on blood pressure and on pain sensation for warm-blooded animals. They are synthesized, e.g., by reducing appropriate 2-benzylpyrrolidines and are formulated into medicament compositions according to established conventional techniques.

2-(Nuclearly-substituted)benzylpyrrolidines

Title compounds and their acid-addition salts are physiologically acceptable or are readily converted to physiologically-acceptable counterparts by established procedures. They are pharmacologically active on the central nervous system (CNS) and are thus useful, when administered to warm-blooded animals, to induce central stimulation, to increase vigilance and to promote normal and pathologically-inhibited drive. They are also useful as analgesics and as blood-pressure-reducing agents for warm-blooded animals. These compounds are prepared, e.g., by reducing an appropriate 2-benzylazacycloheptane and are compounded into normal dosage-form medicament compositions.

Growing community of inventors

Constance, Germany

Klaus Eistetter